
This non‐clinical study and clinical trial (phase II) objective were to examine the safety and efficacy of microwave tissue coagulation (MTC) for prostate cancer and assess its use in lesion‐targeted focal therapy. In the non‐clinical study using Microtaze®‐AFM‐712 (Alfresa‐pharma Corporation) with an MTC needle, MTC was performed by a transperineal approach to canine prostatic‐targeted tissue under real‐time ultrasound guidance. The exploratory clinical trial was conducted to examine the safety and efficacy of MTC. Based on the predictable necrosis, the therapeutic plan (where to place the MTC needle to achieve complete ablation of the target and how many sessions) was strictly determined per patient. The satisfaction of having undergone treatment was very high. All pre‐operative MRI‐visible lesions disappeared, and PSA decreased 55% 6 months after surgery. MTC may be an option for lesion‐targeted focal therapy for prostate cancer.
Like
Save
Share